Hemophilic arthropathy

Summary

Hemophilic arthropathy (MONDO:0043240) is a disease and 11 clinical trials. Top therapeutic interventions include rofecoxib. A subtype of arthritic joint disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemophilic arthropathy
Mondo ID	MONDO:0043240
ICD-10-CM	M36.2
NCIT	C27039
SNOMED CT	80813006
UMLS	C0263725
MedGen	120487
Is cancer (heuristic)	no

Also known as: arthropathy in haemophilia · hemophilic arthritis · hemophilic arthropathy

Disease family

This is a subtype of arthritic joint disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone inflammation disease › arthritic joint disease › hemophilic arthropathy

Related subtypes (12): chondrocalcinosis, transient arthritis, synovitis, osteoarthritis, periarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, reactive arthritis, adult-onset Still disease, polyarticular arthritis, infective arthritis, negative rheumatoid factor polyarthritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04684511	PHASE3	TERMINATED	Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
NCT02994147	PHASE2	COMPLETED	A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
NCT07233122	Not specified	NOT_YET_RECRUITING	MRI Role in Knee Hemophilic Arthopathy
NCT01232634	Not specified	COMPLETED	Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
NCT02569359	Not specified	TERMINATED	Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy
NCT02601170	Not specified	COMPLETED	Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy
NCT04297696	Not specified	COMPLETED	The Effects of Exercises on Gait in Hemophilic Individuals
NCT04309903	Not specified	COMPLETED	The Effects of Manual Therapy in Hemophilic Patients
NCT04535180	Not specified	COMPLETED	Sarcopenia and Osteoporosis in the Patients With Hemophilia
NCT05517070	Not specified	COMPLETED	Vitamin D Deficiency and Body Composition in the Patients With Hemophilia
NCT06952322	Not specified	COMPLETED	Kinesiophobia in the Parents of Hemophilia Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROFECOXIB	4	1